Gilead Sciences Inc. has partnered with the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund) to supply lenacapavir—Gilead’s twice-yearly injectable HIV-1 capsid inhibitor—for the prevention of HIV as pre-exposure prophylaxis (PrEP).

Through the agreement, Gilead will supply enough doses to reach up to two million people over three years in countries supported by the Global Fund, at no profit to Gilead.

Under this strategic partnership agreement with the Global Fund, countries supported by the Global Fund that are among the 120 high-incidence, resource-limited countries can access lenacapavir for PrEP. The Global Fund will prioritize early-access countries based on HIV epidemiology, national prevention strategies, and available resources.

“The agreement between Gilead Sciences and the Global Fund is based on our shared intention to benefit as many people as possible, as quickly as possible with this breakthrough in HIV prevention,” said Daniel O’Day, Chairman and CEO, Gilead Sciences. “We are providing the medicine at no profit to Gilead, and in enough supply to reach up to two million people in low- and lower-middle-income countries ahead of generic lenacapavir becoming available. This is all part of our unprecedented approach to access for a medicine that could help end the HIV epidemic.”

This collaboration is one of several actions Gilead is taking to help ensure supply until licensed generic versions of lenacapavir are available in countries covered by its voluntary licensing program, which is the earliest and most geographically expansive ever developed for an anti-HIV agent.